The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery

Margo Rose F. Macnab; Gabrielle Slater; Mairi Fuller; Beatrix Elsberger; Lesley Lovell; Roger T. Staff; Yazan A. Masannat

doi:10.1016/j.clbc.2022.01.012

The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery

Margo Rose F. Macnab, Gabrielle Slater, Mairi Fuller, Beatrix Elsberger, Lesley Lovell, Roger T. Staff, Yazan A. Masannat^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

Background

Sentinel Lymph Node Biopsy (SLNB) is used to stage the axilla, but there is limited data in patients with prior ipsilateral breast cancer. This study compares redo-SLNB (reSLNB) and Axillary node sample (ANS) in this sub-cohort of patients.

Materials and Methods

This is a retrospective study looking at patients with a new ipsilateral primary or recurrence with history of breast-conserving surgery. Planned and performed surgery, patient demographics and previous treatments were recorded. Node positivity and success rate of reSLNB was analyzed.

Results

A total of 86 patients were identified that had mastectomy for ipsilateral recurrent disease with radiologically negative axilla. Out of the 48 that had reSLNB, 35(72.9%) were successful. Nineteen percent of the reSLNB had positive axillae and 20% of the ANS patients. reSLNB success rate was significantly lower amongst patients with previous axillary surgery (P = .014) and previous positive nodes(P = .001).

Conclusion

reSLNB should be considered to restage the axilla in patients with previous history of ipsilateral cancer especially that there is growing evidence showing good identification rate.

Original language	English
Pages (from-to)	e674-e679
Number of pages	6
Journal	Clinical Breast Cancer
Volume	22
Issue number	5
Early online date	17 Jun 2022
DOIs	https://doi.org/10.1016/j.clbc.2022.01.012
Publication status	Published - Jul 2022

Bibliographical note

Acknowledgments
There is no funding for this project as this is a retrospective review of our practice. This project did not get any grants or funding in the public, commercial or a none profit sector. Open Access via Elsevier agreement.

Data Availability Statement

The data collected was anonymized and analyzed and the data analyzed is included in the tables. We don't have the permission to publicly share the data from the Caldicott Guardian application through the local governance department, but the data will be kept for few years after publication with the corresponding Author (YM) and any further enquiries can be directed to him.

Keywords

Axillary node sample
Axillary Surgery
Breast cancer recurrence
Breast surgery
Sentinel node biopsy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clbc.2022.01.012Licence: CC BY-NC-ND

Macnab_etal_CBC_TheRoleofRedo_VOR
This article is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 4.0 International License, which permits non-commercial use, sharing and reproduction in any medium or format, as long as you do not change or modify the original and give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. https://creativecommons.org/licenses/by-nc-nd/4.0/
Final published version, 470 KBLicence: CC BY-NC-ND

Cite this

@article{4919059cdebd4a61b5093e78608bf445,

title = "The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery",

abstract = "BackgroundSentinel Lymph Node Biopsy (SLNB) is used to stage the axilla, but there is limited data in patients with prior ipsilateral breast cancer. This study compares redo-SLNB (reSLNB) and Axillary node sample (ANS) in this sub-cohort of patients.Materials and MethodsThis is a retrospective study looking at patients with a new ipsilateral primary or recurrence with history of breast-conserving surgery. Planned and performed surgery, patient demographics and previous treatments were recorded. Node positivity and success rate of reSLNB was analyzed.ResultsA total of 86 patients were identified that had mastectomy for ipsilateral recurrent disease with radiologically negative axilla. Out of the 48 that had reSLNB, 35(72.9%) were successful. Nineteen percent of the reSLNB had positive axillae and 20% of the ANS patients. reSLNB success rate was significantly lower amongst patients with previous axillary surgery (P = .014) and previous positive nodes(P = .001).ConclusionreSLNB should be considered to restage the axilla in patients with previous history of ipsilateral cancer especially that there is growing evidence showing good identification rate.",

keywords = "Axillary node sample, Axillary Surgery, Breast cancer recurrence, Breast surgery, Sentinel node biopsy",

author = "Macnab, {Margo Rose F.} and Gabrielle Slater and Mairi Fuller and Beatrix Elsberger and Lesley Lovell and Staff, {Roger T.} and Masannat, {Yazan A.}",

note = "Acknowledgments There is no funding for this project as this is a retrospective review of our practice. This project did not get any grants or funding in the public, commercial or a none profit sector. Open Access via Elsevier agreement.",

year = "2022",

month = jul,

doi = "10.1016/j.clbc.2022.01.012",

language = "English",

volume = "22",

pages = "e674--e679",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery

AU - Macnab, Margo Rose F.

AU - Slater, Gabrielle

AU - Fuller, Mairi

AU - Elsberger, Beatrix

AU - Lovell, Lesley

AU - Staff, Roger T.

AU - Masannat, Yazan A.

N1 - Acknowledgments There is no funding for this project as this is a retrospective review of our practice. This project did not get any grants or funding in the public, commercial or a none profit sector. Open Access via Elsevier agreement.

PY - 2022/7

Y1 - 2022/7

N2 - BackgroundSentinel Lymph Node Biopsy (SLNB) is used to stage the axilla, but there is limited data in patients with prior ipsilateral breast cancer. This study compares redo-SLNB (reSLNB) and Axillary node sample (ANS) in this sub-cohort of patients.Materials and MethodsThis is a retrospective study looking at patients with a new ipsilateral primary or recurrence with history of breast-conserving surgery. Planned and performed surgery, patient demographics and previous treatments were recorded. Node positivity and success rate of reSLNB was analyzed.ResultsA total of 86 patients were identified that had mastectomy for ipsilateral recurrent disease with radiologically negative axilla. Out of the 48 that had reSLNB, 35(72.9%) were successful. Nineteen percent of the reSLNB had positive axillae and 20% of the ANS patients. reSLNB success rate was significantly lower amongst patients with previous axillary surgery (P = .014) and previous positive nodes(P = .001).ConclusionreSLNB should be considered to restage the axilla in patients with previous history of ipsilateral cancer especially that there is growing evidence showing good identification rate.

AB - BackgroundSentinel Lymph Node Biopsy (SLNB) is used to stage the axilla, but there is limited data in patients with prior ipsilateral breast cancer. This study compares redo-SLNB (reSLNB) and Axillary node sample (ANS) in this sub-cohort of patients.Materials and MethodsThis is a retrospective study looking at patients with a new ipsilateral primary or recurrence with history of breast-conserving surgery. Planned and performed surgery, patient demographics and previous treatments were recorded. Node positivity and success rate of reSLNB was analyzed.ResultsA total of 86 patients were identified that had mastectomy for ipsilateral recurrent disease with radiologically negative axilla. Out of the 48 that had reSLNB, 35(72.9%) were successful. Nineteen percent of the reSLNB had positive axillae and 20% of the ANS patients. reSLNB success rate was significantly lower amongst patients with previous axillary surgery (P = .014) and previous positive nodes(P = .001).ConclusionreSLNB should be considered to restage the axilla in patients with previous history of ipsilateral cancer especially that there is growing evidence showing good identification rate.

KW - Axillary node sample

KW - Axillary Surgery

KW - Breast cancer recurrence

KW - Breast surgery

KW - Sentinel node biopsy

UR - http://www.scopus.com/inward/record.url?scp=85126002966&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2022.01.012

DO - 10.1016/j.clbc.2022.01.012

M3 - Article

AN - SCOPUS:85126002966

SN - 1526-8209

VL - 22

SP - e674-e679

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 5

ER -

The Role of redo-Sentinel Lymph Node Biopsy in Patients With Prior Ipsilateral Breast Cancer Surgery

Abstract

Bibliographical note

Data Availability Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this